Assembly Biosciences Inc (VTUS)
Ventrus Biosciences is a development stage pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically anal disorders. Co.'s product candidate portfolio consists of two in-licensed late-stage drugs: VEN 307 (topical diltiazem), which is intended to treat pain associated with anal fissures; and VEN 308 (topical phenylephrine), which is intended to treat fecal incontinence. These candidates are two molecules that were previously approved and as of Dec 31 2012, were marketed for other indications and that have been formulated into Co.'s topical treatments for these new gastrointestinal indications.
|
Free VTUS Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|